CompletedNot Applicable

Medication Reconciliation in Pulmonary Hypertension

France129 participantsStarted 2021-02-16

Plain-language summary

Pulmonary hypertension (PH) is a life threatening condition. In PH, pulmonary arterial hypertension (PAH) and chronic thrombo-embolic chronic pulmonary hypertension (CTEPH) are two rare diseases requiring specific and complex drug management. In France ,a part of these treatments ,only available in hospital pharmacies, are generally unknown from community health care professionals despite the high risk of drug-interactions and side effects. Anticipating medication errors at the begging of the disease is therefore important, and could be done through medication reconciliation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient affiliated or entitled to a social security scheme * At least 18 years old * Patient with enlightened information of the study and not opposed with it. * For patient without MR: patient hospitalized for the first re-evaluation of PAH or CTEPH within 12 months following the first assessment hospitalization (ie: first right heart catheterization at bicetre Hospital). * For patient with MR: patient hospitalized for first assessment (first right heart catheterization at bicetre Hospital) of PAH or CTEPH Exclusion Criteria: * Patient suffering from another form of PH * Patient under guardianship or curator * Inability to give information to the patient either due to language barrier or to cognitive impairment * Patient hosted in institution on discharge from hospital (follow-up care and long-term rehabilitation) * Patient with a life expectancy of less than 1 year * Patient on transplant list * Patient refusal * Length of stay \< 48 hours

What they're measuring

Proportion of patients having at least one medication error on discharge at the first hospitalization.

Timeframe: 12months

Trial details

NCT IDNCT04744584

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-15